TAK-041

DRUG2 trials

Sponsors

Neurocrine Biosciences

Conditions

Healthy VolunteersSchizophreniaStable Schizophrenia

Phase 1

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

CompletedNCT02748694

Neurocrine BiosciencesHealthy Volunteers, Schizophrenia

Start: 2016-05-09End: 2019-09-22Updated: 2021-03-19

Phase 2

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

CompletedNCT03319953

Neurocrine BiosciencesStable Schizophrenia

Start: 2017-12-21End: 2019-11-06Updated: 2021-03-19

Related Papers

The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial

Psychopharmacology2025-08-161 citations

A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia

British Journal of Clinical Pharmacology2022-03-1215 citations